Showing results (41-50 of 6,841) with videos related to

Sort By:
Pageof 685
Health Policy (Amsterdam, Netherlands)|July 27, 2020
Examining the variation across acute trusts in patient delayed dischargeRussell DeVolder, Victoria Serra-Sastre, Bernarda Zamora
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2021
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancerBoshen Jiao, Louis P Garrison
Pharmacoeconomics|January 19, 2013
Operationalizing value-based pricing of medicines : a taxonomy of approachesJon Sussex, Adrian Towse, Nancy Devlin
Cost Effectiveness and Resource Allocation : C/E|September 10, 2020
Establishing a reasonable price for an orphan drugMikel Berdud, Michael Drummond, Adrian Towse
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 17, 2025
Pricing combination products: not how but who?Adrian Towse, Andrew Briggs, Lotte Steuten
International Journal of Technology Assessment in Health Care|May 31, 2017
ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIAGrace Hampson, Chris Henshall, Adrian Towse
Frontiers in Health Services|September 11, 2023
A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approachMikel Berdud, Jimena Ferraro, Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021
Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World DataWoojung Lee, Meng Li, William B Wong, et al.
Journal of Managed Care & Specialty Pharmacy|August 25, 2021
Real-world evidence for option value in metastatic melanomaWilliam B Wong, Tu My To, Meng Li, et al.
Pageof 685